Trial · NCT01813136
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
NCT01813136, Phase 2, Completed, Centre Leon Berard
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma. Trials, record NCT01813136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01813136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
- NCT number
- NCT01813136
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 168 participants, actual
- Lead sponsor
- Centre Leon Berard
- Conditions
- Thyroid Carcinoma
- Interventions
- Continuous pazopanib (Arm A), Intermittent pazopanib (Arm B)
- First posted
- 2013-03-18
- Last updated
- 2026-07-02
- Other registries' IDs
- eudract:2012-003162-41
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to treatment failure (TTF) | up to 36 months | TTF is the time to permanent treatment discontinuation due to any cause after randomization in each arm |
| Secondary | Objective Response Rate (ORR) | 6 months after inclusion | Proportion of patients with a best overall response of Complete Response (CR) or a Partial Response (PR) at the end of the first 6 cycles, according to RECIST criteria 1.1 |
| Secondary | Disease Control Rate (DCR) | 6 months after inclusion | Proportion of patients with a best overall response of Complete Response, Partial Response or Stable Disease at the end of the first 6 cycles, according to RECIST criteria 1.1 |
| Secondary | Progression-Free Survival (PFS) | up to 36 months | Time from date of randomization to the date of event defined as the first documented progression under treatment or death due to any cause. |
| Secondary | Best response rate | up to 36 months | Best response observed from date of randomization |
| Secondary | Duration of response | up to 36 months | Time from the first documented response (CR or PR) to the first documented disease progression or death due to any cause, applies only to patients whose best overall response is CR or PR |
| Secondary | Overall Survival (OS) | up to 36 months | Time from date of randomization to the date of death due to any cause |
| Secondary | Objective Response Rate (ORR) | 6 months after randomization | Proportion of patients with a CR or a PR after 6 cycles from randomization. |
| Secondary | Disease Control Rate (SDR) | 6 months after randomization | The proportion of patients with a SD, PR or CR after 6 cycles from randomization. |
| Secondary | Safety profile of pazopanib | up to 36 months | Adverse events (AE) experienced throughout the study and assessed according the NCI-CTC AE version 4.0. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01813136
GET https://conductscience.org/api/trials/v1/NCT01813136/papers?page=2